Enhabit (NYSE:EHAB - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Enhabit to post earnings of $0.04 per share for the quarter. Enhabit has set its FY 2024 guidance at 0.190-0.370 EPS.Investors that wish to register for the company's conference call can do so using this link.
Enhabit (NYSE:EHAB - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.02. The firm had revenue of $260.60 million for the quarter, compared to analyst estimates of $265.99 million. Enhabit had a negative net margin of 0.84% and a positive return on equity of 1.61%. During the same quarter in the previous year, the business posted $0.04 EPS. On average, analysts expect Enhabit to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Enhabit Stock Down 0.7 %
Shares of Enhabit stock traded down $0.05 during trading hours on Wednesday, hitting $6.93. 80,759 shares of the company's stock traded hands, compared to its average volume of 587,300. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.73. Enhabit has a twelve month low of $6.89 and a twelve month high of $11.74. The stock has a 50 day simple moving average of $7.71 and a 200-day simple moving average of $8.71. The company has a market cap of $348.46 million, a PE ratio of -41.00 and a beta of 1.81.
Insiders Place Their Bets
In related news, Director Jeffrey Bolton purchased 5,000 shares of the business's stock in a transaction that occurred on Thursday, August 22nd. The shares were purchased at an average cost of $8.01 per share, with a total value of $40,050.00. Following the completion of the acquisition, the director now directly owns 78,877 shares of the company's stock, valued at approximately $631,804.77. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.90% of the stock is owned by company insiders.
About Enhabit
(
Get Free Report)
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Featured Stories
Before you consider Enhabit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enhabit wasn't on the list.
While Enhabit currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.